These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22851268)

  • 21. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
    Brauch H; Schroth W; Goetz MP; Mürdter TE; Winter S; Ingle JN; Schwab M; Eichelbaum M
    J Clin Oncol; 2013 Jan; 31(2):176-80. PubMed ID: 23091108
    [No Abstract]   [Full Text] [Related]  

  • 22. CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.
    Margolin S; Lindh JD; Thorén L; Xie H; Koukel L; Dahl ML; Eliasson E
    Pharmacogenomics; 2013 Apr; 14(6):613-22. PubMed ID: 23570465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming recurrence risk: extended adjuvant endocrine therapy.
    Cianfrocca M
    Clin Breast Cancer; 2008 Dec; 8(6):493-500. PubMed ID: 19073503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
    Pennery E
    Eur J Oncol Nurs; 2008 Jul; 12(3):233-43. PubMed ID: 18372213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
    Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
    Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ethics of CYP2D6 testing for patients considering tamoxifen.
    Hartman AR; Helft P
    Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anastrozole.
    Cuzick J
    Drugs Today (Barc); 2005 Apr; 41(4):227-39. PubMed ID: 16034487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.
    Ahern TP; Christensen M; Cronin-Fenton DP; Lunetta KL; Søiland H; Gjerde J; Garne JP; Rosenberg CL; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
    Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1937-43. PubMed ID: 21750172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
    Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
    Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
    Ravdin P
    Lancet; 2002 Jun; 359(9324):2126-7. PubMed ID: 12090973
    [No Abstract]   [Full Text] [Related]  

  • 35. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen.
    Dieudonné AS; Lambrechts D; Smeets D; Belmans A; Wildiers H; Paridaens R; Hyonil C; Timmerman D; Christiaens MR; Vergote I; Neven P
    Ann Oncol; 2014 Jan; 25(1):90-5. PubMed ID: 24265353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
    Mouridsen HT; Chaudri-Ross HA
    Eur J Cancer; 2004 May; 40(7):1095-6; author reply 1097. PubMed ID: 15093587
    [No Abstract]   [Full Text] [Related]  

  • 39. Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
    Bonanni B; Serrano D; Gandini S; Guerrieri-Gonzaga A; Johansson H; Macis D; Cazzaniga M; Luini A; Cassano E; Oldani S; Lien EA; Pelosi G; Decensi A
    Clin Cancer Res; 2009 Nov; 15(22):7053-60. PubMed ID: 19887477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
    Kaufmann M; Rody A
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):487-94. PubMed ID: 15915367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.